NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
54868-3826-03 | 54868-3826 | Methotrexate sodium | Methotrexate Sodium | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 5, 2007 | In Use | |
54868-5427-02 | 54868-5427 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 9, 2005 | Jun 30, 2013 | No Longer Used | |
00703-3218-01 | 00703-3218 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 5, 2020 | In Use | |
00703-3218-81 | 00703-3218 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 5, 2020 | In Use | |
25021-0214-05 | 25021-0214 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 20, 2012 | Dec 27, 2016 | No Longer Used |
70710-1895-06 | 70710-1895 | Arsenic trioxide | Arsenic trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb 28, 2023 | In Use | |
00703-4244-81 | 00703-4244 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 15, 2016 | In Use | |
47781-0610-23 | 47781-0610 | Cisplatin | Cisplatin | 100.0 mg/100mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 25, 2017 | Mar 1, 2020 | No Longer Used |
46014-1195-03 | 46014-1195 | talazoparib | Talzenna | 1.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Oct 26, 2018 | In Use | |
16729-0092-03 | 16729-0092 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 28, 2011 | In Use | |
68001-0266-32 | 68001-0266 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec 16, 2014 | In Use | |
54868-4142-03 | 54868-4142 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 29, 2005 | In Use | |
51991-0821-28 | 51991-0821 | Everolimus | Everolimus | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
47335-0929-72 | 47335-0929 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
00781-2693-44 | 00781-2693 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
55150-0497-10 | 55150-0497 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Apr 8, 2022 | In Use | |
55390-0069-01 | 55390-0069 | Vinorelbine | Vinorelbine | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Feb 11, 2004 | Dec 31, 2012 | No Longer Used | ||
52609-3001-00 | 52609-3001 | Melphalan Hydrochloride | Alkeran | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jan 1, 2011 | In Use | ||
00054-0249-13 | 00054-0249 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
15054-0043-01 | 15054-0043 | Irinotecan Hydrochloride | Onivyde | 4.3 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Oct 22, 2015 | In Use | |
62856-0712-30 | 62856-0712 | Lenvatinib | Lenvima | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Aug 15, 2018 | In Use | |
62856-0720-05 | 62856-0720 | Lenvatinib | Lenvima | 10.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | |
00078-1161-47 | 00078-1161 | Trametinib | Mekinist | 0.05 mg/mL | Chemotherapy | MEK Inhibitor | BRAF | Oral | Mar 16, 2023 | In Use | |
65219-0552-02 | 65219-0552 | Pralatrexate | Pralatrexate | 40.0 mg/2mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Nov 15, 2022 | In Use | |
43598-0046-63 | 43598-0046 | SUNITINIB MALATE | SUNITINIB MALATE | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov 30, 2022 | In Use |
Found 11465 results — Export these results